Review of NICE Technology Appraisal Guidance No. 197; Dronedarone for the treatment of non-permanent atrial fibrillation

The Institute was proposing that TA197 should be incorporated into the ongoing update of NICE clinical guideline 36 Atrial fibrillation, once the wording of the guidance has been amended to reflect the changes to the UK marketing authorisation for dronedarone.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal.

We will therefore formally re-issue the guidance with amended wording in recommendation 1.1 to reflect the restricted marketing authorisation for dronedarone.  The re-issued guidance will then be incorporated into the ongoing update of CG36. 

In the meantime, an transitory statement notifying stakeholders of the restricted marketing authorisation for dronedarone has been published on the Institute’s website.

October 2012